These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 11457514)

  • 1. Characterization of the type A cholecystokinin receptor hormone-binding domain: use of contrasting and complementary methodologies.
    Ding XQ; Miller LJ
    Peptides; 2001 Aug; 22(8):1223-8. PubMed ID: 11457514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insights into the molecular basis of ligand binding by the cholecystokinin receptor.
    Miller LJ; Ding XQ
    Pancreatology; 2001; 1(4):336-42. PubMed ID: 12120212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elucidation of the molecular basis of cholecystokinin Peptide docking to its receptor using site-specific intrinsic photoaffinity labeling and molecular modeling.
    Dong M; Lam PC; Pinon DI; Abagyan R; Miller LJ
    Biochemistry; 2009 Jun; 48(23):5303-12. PubMed ID: 19441839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Key differences in molecular complexes of the cholecystokinin receptor with structurally related peptide agonist, partial agonist, and antagonist.
    Arlander SJ; Dong M; Ding XQ; Pinon DI; Miller LJ
    Mol Pharmacol; 2004 Sep; 66(3):545-52. PubMed ID: 15322246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Refinement of the conformation of a critical region of charge-charge interaction between cholecystokinin and its receptor.
    Ding XQ; Pinon DI; Furse KE; Lybrand TP; Miller LJ
    Mol Pharmacol; 2002 May; 61(5):1041-52. PubMed ID: 11961122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular basis of agonist binding to the type A cholecystokinin receptor.
    Miller LJ; Lybrand TP
    Pharmacol Toxicol; 2002 Dec; 91(6):282-5. PubMed ID: 12688369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential docking of high-affinity peptide ligands to type A and B cholecystokinin receptors demonstrated by photoaffinity labeling.
    Dong M; Liu G; Pinon DI; Miller LJ
    Biochemistry; 2005 May; 44(17):6693-700. PubMed ID: 15850403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measurement of intermolecular distances for the natural agonist Peptide docked at the cholecystokinin receptor expressed in situ using fluorescence resonance energy transfer.
    Harikumar KG; Pinon DI; Wessels WS; Dawson ES; Lybrand TP; Prendergast FG; Miller LJ
    Mol Pharmacol; 2004 Jan; 65(1):28-35. PubMed ID: 14722234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Refinement of the structure of the ligand-occupied cholecystokinin receptor using a photolabile amino-terminal probe.
    Ding XQ; Dolu V; Hadac EM; Holicky EL; Pinon DI; Lybrand TP; Miller LJ
    J Biol Chem; 2001 Feb; 276(6):4236-44. PubMed ID: 11050076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of lysine187 within the second extracellular loop of the type A cholecystokinin receptor in agonist-induced activation. Use of complementary charge-reversal mutagenesis to define a functionally important interdomain interaction.
    Dong M; Ding XQ; Thomas SE; Gao F; Lam PC; Abagyan R; Miller LJ
    Biochemistry; 2007 Apr; 46(15):4522-31. PubMed ID: 17381074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel benzodiazepine photoaffinity probe stereoselectively labels a site deep within the membrane-spanning domain of the cholecystokinin receptor.
    Hadac EM; Dawson ES; Darrow JW; Sugg EE; Lybrand TP; Miller LJ
    J Med Chem; 2006 Feb; 49(3):850-63. PubMed ID: 16451051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A peptide agonist acts by occupation of a monomeric G protein-coupled receptor: dual sites of covalent attachment to domains near TM1 and TM7 of the same molecule make biologically significant domain-swapped dimerization unlikely.
    Hadac EM; Ji Z; Pinon DI; Henne RM; Lybrand TP; Miller LJ
    J Med Chem; 1999 Jun; 42(12):2105-11. PubMed ID: 10377216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct identification of a distinct site of interaction between the carboxyl-terminal residue of cholecystokinin and the type A cholecystokinin receptor using photoaffinity labeling.
    Ji Z; Hadac EM; Henne RM; Patel SA; Lybrand TP; Miller LJ
    J Biol Chem; 1997 Sep; 272(39):24393-401. PubMed ID: 9305898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Arginine 197 of the cholecystokinin-A receptor binding site interacts with the sulfate of the peptide agonist cholecystokinin.
    Gigoux V; Maigret B; Escrieut C; Silvente-Poirot S; Bouisson M; Fehrentz JA; Moroder L; Gully D; Martinez J; Vaysse N; Fourmy AD
    Protein Sci; 1999 Nov; 8(11):2347-54. PubMed ID: 10595537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Moleular models for cholecystokinin-A receptor.
    Dawson ES; Henne RM; Miller LJ; Lybrand TP
    Pharmacol Toxicol; 2002 Dec; 91(6):290-6. PubMed ID: 12688371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluorescence resonance energy transfer analysis of the antagonist- and partial agonist-occupied states of the cholecystokinin receptor.
    Harikumar KG; Miller LJ
    J Biol Chem; 2005 May; 280(19):18631-5. PubMed ID: 15757907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct identification of the agonist binding site in the human brain cholecystokininB receptor.
    Anders J; Blüggel M; Meyer HE; Kühne R; ter Laak AM; Kojro E; Fahrenholz F
    Biochemistry; 1999 May; 38(19):6043-55. PubMed ID: 10320330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct demonstration of unique mode of natural peptide binding to the type 2 cholecystokinin receptor using photoaffinity labeling.
    Dong M; Miller LJ
    Peptides; 2013 Aug; 46():143-9. PubMed ID: 23770253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of ligand-receptor interactions of cholecystokinin by nuclear magnetic resonance.
    Giragossian C; Mierke DF
    Life Sci; 2003 Jun; 73(6):705-13. PubMed ID: 12801592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Photoaffinity labeling of rat pancreatic cholecystokinin type A receptor antagonist binding sites demonstrates the presence of a truncated cholecystokinin type A receptor.
    Poirot SS; Escrieut C; Dufresne M; Martinez J; Bouisson M; Vaysse N; Fourmy D
    Mol Pharmacol; 1994 Apr; 45(4):599-607. PubMed ID: 8183238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.